Targeting tauopathy with engineered tau-degrading intrabodies

Targeting tauopathy with engineered tau-degrading intrabodies

Abstract Background The accumulation of pathological tau is the main component of neurofibrillary tangles and other tau aggregates in several neurodegenerative diseases, referred to as tauopathies. Recently, immunotherapeutic approaches targeting tau have been demonstrated to be beneficial in decrea...

Full description

Bibliographic Details
Main Authors: Gilbert Gallardo, Connie H. Wong, Sara M. Ricardez, Carolyn N. Mann, Kent H. Lin, Cheryl E. G. Leyns, Hong Jiang, David M. Holtzman
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Molecular Neurodegeneration
Subjects:
Alzheimer’s disease
Tauopathy
Immunotherapy
Intrabodies
Tau degradation
Online Access:http://link.springer.com/article/10.1186/s13024-019-0340-6

Internet

http://link.springer.com/article/10.1186/s13024-019-0340-6

Similar Items